Christina Claus studied biology and organic chemistry at the Heinrich Heine University (Germany) and University of Bielefeld (Germany) and graduated 2005. During her studies she was supported by a scholarship of the "Studienstiftung des deutschen Volkes". After working for nearly a year as a scientific associate she started her PhD at the graduate school University Berne, Switzerland in Cellular and Biomedical Science (GCB). She graduated 2010 in the lab of Prof. Dr. Adrian F. Ochsenbein MD, investigating the role of CD27 (TNFRSF7) in chronic viral infections and solid tumors. After a short PostDoc at the Inselspital in Bern she started 2011 as an RPF PostDoc at Roche Glycart (Zurich, Switzerland) focusing on the role of 4-1BB (CD137, TNFRSF9) in cancer immunology supervised by Dr. Victor Levitsky M.D. and Dr. Hy Levitsky, M.D. (John Hopkins University School of Medicine, academic supervisor). 2013 she became Scientist at the Roche Innovation Center Zurich focusing on the development of tumor-targeted 4-1BB agonists and the establishment of the 4-1BB platform. In a big team effort two molecules coming from this platform have entered the clinic recently (FAP-4-1BBL and CD19-4-1BBL). Since 2016 she works as a research project leader and is leading a lab in the department of Cancer Immunotherapy 3 (CIT-3), headed by Dr. Christian Klein, at the Roche Innovation Center Zurich, headed by Dr. Pablo Umana.